Reactions Weekly

, Volume 1471, Issue 1, pp 4–4

Gliptins neither benefit nor harm T2DM cardiovascular outcomes

Clinical study

References

  1. 1.
    Astra Zeneca, et al. ONGLYZA(Rm) (saxagliptin) achieves primary safety endpoint, demonstrating no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial. Media Release : 2 Sep 2013. Available from: URL: http://www.astrazeneca.com
  2. 2.
    Scirica BM, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine : [9 pages], 2 Sep 2013. Available from: URL: http://dx.doi.org/10.1056/NEJMoa1307684
  3. 3.
    White WB, et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine : [9 pages], 2 Sep 2013. Available from: URL: http://dx.doi.org/10.1056/NEJMoa1305889

Copyright information

© Springer International Publishing Switzerland 2013

Personalised recommendations